Usana Health Sciences Inc (USNA) - Comprehensive Stock Analysis & Investment Research
Deep dive into Usana Health Sciences Inc's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.
Usana Health Sciences Inc Investment Summary
When evaluating whether Usana Health Sciences Inc (USNA) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.
Company Profile
Usana Health Sciences Inc (USNA) operates within the Life Sciences sector, specifically in the Medicinal Chemicals & Botanical Products industry. The company employs approximately 8,320 people. With a market capitalization of $318 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.
Financial Performance Analysis
Our comprehensive financial analysis covers Usana Health Sciences Inc's revenue, profitability metrics, balance sheet strength, and cash flow generation...
AI Price Predictions
Get AI-powered 7-day, 30-day and 90-day price forecasts for Usana Health Sciences Inc along with confidence scores and detailed analysis...
Investment Considerations
Expert analysis of whether Usana Health Sciences Inc is suitable for your investment objectives, risk tolerance, and time horizon...
Corporate Identity
Usana Health Sciences Inc (Stock Symbol: USNA) is a prominent company operating within the Life Sciences sector, with a specific focus on the Medicinal Chemicals & Botanical Products industry. The company's shares are publicly traded on the NYSE exchange.
Leadership & Workforce
Detailed information about Usana Health Sciences Inc's leadership team, workforce size, and organizational structure...
Market Classification
Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Usana Health Sciences Inc...
Sector & Industry Analysis
In-depth sector dynamics and industry context for Usana Health Sciences Inc...
Revenue & Growth Analysis
Usana Health Sciences Inc generates annual revenues of $925 million , representing an emerging company in its growth phase.
Profitability Metrics
Net profit margin, gross margin, and operating margin analysis for Usana Health Sciences Inc...
Market Valuation
P/E ratio, price-to-book, and valuation multiples for Usana Health Sciences Inc...
Return Metrics
Return on equity (ROE), return on assets (ROA), and capital efficiency for Usana Health Sciences Inc...
Strategic Market Position
Usana Health Sciences Inc strategically competes in the highly dynamic Medicinal Chemicals & Botanical Products marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.
Industry Competitive Landscape
Usana Health Sciences Inc competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.
Operational Efficiency
The company shows positive operational efficiency through free cash flow generation of $108 million annually , with year-over-year cash flow growth of 26.6%. Positive free cash flow indicates the business generates more cash than required for operations and capital investments, providing resources for growth initiatives or shareholder returns.
Margin & Pricing Power Analysis
The company maintains a 256.9% gross margin which reflects exceptional pricing power and/or an asset-light business model. Gross margins at this level are typically seen in software, pharmaceuticals, or luxury goods companies where the cost of incremental production is minimal relative to selling prices. Such margins indicate significant competitive advantages protecting the company from price-based competition.
Operating margin of 30.4% demonstrates how efficiently the company converts revenues into operating profits after accounting for all operating expenses including research and development, sales and marketing, and general administrative costs. This strong operating margin indicates excellent cost control and efficient organizational structure relative to the revenue base.
Asset Utilization Efficiency
Asset turnover ratio of 1.99x indicates exceptional efficiency in utilizing company assets to generate revenue. High asset turnover is characteristic of retail, distribution, or service businesses that operate with relatively lean asset bases. This efficiency translates to higher returns on invested capital when combined with reasonable margins.
Financial Strength & Leverage
Current ratio of 2.30 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.